Top Health News

WASHINGTON (Reuters) – Japan's Takeda Pharmaceutical Co said on Wednesday it submitted a newborn take covering in the United States for a hypertension drug.

A U.S. supplementary of Takeda, Japan's maximal drugmaker, submitted the covering to the U.S. Food and Drug Administration after completing four phase 3 clinical trials with more than 4,000 hypertension patients.

Hypertension, or broad blood pressure, affects nearly digit in three adults in the United States.

If the covering holds up to a origin review, the bureau typically decides whether to approve a take for understanding within most 10 months.

The newborn take combines azilsartan medoxomil, a medication discovered by Takeda that lowers blood push by interference a destined hormone, with chlorthalidone, a long-acting oral diuretic.

"Millions of patients with hypertension do not have their information under control," said Darryl Sleep, vice president of clinical science for Takeda Global Research & Development Center, Inc. U.S., a supplementary of the Asian pharmaceutical company.

Sleep additional that the newborn compound "could potentially wage an important newborn treatment choice for patients with hypertension and the upbeat care providers who control them."

The dweller Heart Association institute that hypertension accounted for more than $73 billion in U.S. healthcare expenses in 2009.

(Reporting by Jasmin Melvin; Editing by Gary Hill)

Source